Bronchial asthma is the syndrome, characterized with chronic inflammation, hyperreactivity and obstruction of the respiratory pathways, accompanied with consequential symptoms and remodeling of the respiratory pathways. Application of inhaled corticosteroids accompanied with appropriate education of patients, significantly improve therapeutic treatment and outcome of the asthma. But, improvement of the lung function and patients subjective state is remarkable better yif inhaled corticosteroids are combined with adrenergic â2 agonists, than if the dose of inhaled corticosteroids is increased. So, according to Global initiative for asthma and clinical results long acting adrenergic â2 agonists in combination with inhaled corticosteroids are most efficient in asthma treatment and establishment and conservation of bronchial asthma control.
Nelson HS. The Salmeterol Multicenter Asthma Research Trial: a comparison of usual pharmacotherapy for asthma or usual pharmacotherapy plus salmeterol. Chest. 129:15–26.
2.
Beasley R. A historical perspective of the New Zealand asthma mortality epidemics. J Allergy Clin Immunol. 117:225–8.
3.
Pearce NE, Hensley MJ. Epidemiologic studies of β-agonists and asthma deaths. Epidemiol Rev. 20:173–86.
4.
Barnes PJ. Effect of β-agonists on inflammatory cells. J Allergy Clin Immunol. 104:10–7.
5.
Bateman ED, Fennell L, Lombardi DM, English R. Budesonide/formoterol and formoterol provide similar rapid relief in patients with acute asthma showing refractoriness to salbutamol. Respir Res. 7(13).
6.
Bateman ED, Boushey HA, Bousquet J, Busse WW, Clark TJ, Pauwels, et al. Can guideline-defined asthma control be achieved? The Gaining Optimal Asthma Control Study. Am J Respir Crit Care Med. 170:836–44.
7.
Pauwels RA, Lotvall J, Postma DS, Tattersfield AE, O’Byrne PM, Barnes PJ, et al. Effect of inhaled formoterol and budesonide on exacerbation of asthma. Formoterol and Corticosteroids Establishing Therapy (FACET. International Study Group N Engl J Med. 337:1405–11.
8.
Lazarus SC, Boushey HA, Foly JV, Chincilli VM, Lemanske RF. Long-acting β-agonists monotherapy vs continued therapy with inhaled corticosteroids in patients with persistent asthma. JAMA. 285:2583–93.
9.
Kips JC, Pauwels RA. Long-acting inhaled β-agonists therapy in asthma. Am J Respir Crit Care Med. 164(6):923–32.
10.
Bateman ED, Fennell L, Lombardi DM, English R. Budesonide/formoterol and formoterol provide similar rapid relief in patients with acute asthma showing refractoriness to salbutamol. Respir Res. 7(13).
11.
Pearce NE. Epidemiology of asthma mortality. In: Asthma and Rhinitis. p. 56–72.
12.
Spitzer WO. The use of β-agonists and the risk of death and near death from asthma. N Engl J Med. 326:501–6.
13.
Nelson HS. The Salmeterol Multicenter Asthma Research Trial: a comparison of usual pharmacotherapy for asthma or usual pharmacotherapy plus salmeterol. Chest. 129:15–26.
14.
Moore RH, Millman EE, Godines V, Hanania NA. Salmeterol stimulation dissociates β-adrenergic receptor phosphorylation and internalization. Am J Respir Cell Mol Biol. 36:254–61.
15.
Wechsler ME. β-adrenergic receptor polymorphisms and response to salmeterol. Am J Respir Crit Care Med. 173:519–26.
16.
Woolcock AJ, Lundback B, Ringdal N, Jacques LA. Comparison of addition of salmeterol to inhaled steroids with doubling of the inhaled steroids. Am J Respir Crit Care Med. 153:1481–8.
17.
Lemanske RF, Sorkness CA, Mauger EA, Lazarus SC, Boushey HA, Foly JV, et al. Asthma Clinical Research Network. Inhaled corticosteroid reduction and elimination in patients with persistent asthma receiving salmeterol: a randomized controlled trial. JAMA. 285:2594–603.
18.
O’Byrne PM. Adelroth E. β deja vu. Chest. 129:3–5.
19.
Nelson HS, Dorinsky PM. Safety of long-acting β-agonists. Ann Intern Med. 145(706).
20.
Peek EJ, Richards DF, Faith P, Lavender T, Lee H, Corrigan J, et al. Interleukin 10 secreting “regulatory” T cells induced by glucocorticoids and β agonists. Am J Respir Cell Mol Biol. 33:105–11.
21.
Melland B. The treatment of spasmodic asthma by the hypodermic injection of adrenalin. Lancet. 1407–11.
22.
Pavlov N. Funkcionalna dijagnostika i nadzor djece s astmom. Paediatr Croat. 51(1):85–90.
23.
Umland SP, Schleimer RP, Johnston SL. Review of the molecular and cellular mechanisms of action of glucocorticoids for use in asthma. Pulm Pharmacol Ther. 15(1):35–50.
24.
Graeme P, Currie SS. What about add-on second-line controller therapy? Chest. 127:1077–8.
25.
Suissa S, Ernst P, Benayoun S, Baltzan M, Cai B. Low dose inhaled corticosteroid and the prevention of death from asthma. N Engl J Med. 343(5):332–6.
26.
Jayasairi B, Perera C. Successful withdrawal of inhaled corticoids in childhood asthma. Respirology. 10:385–8.
27.
Thomas WS. Ephedrine in asthma: a clinical report. Am J Med Sci. 171–9.
28.
Chu EK, Asthma DJM. One hundred years of treatment and onward. Am J Respir Crit Care Med. 171:1202–8.
29.
Global Initiative for Asthma. Global Strategy for Asthma Management and Prevention.
30.
N Engl J Med NHS.
31.
Shore SA, Drazen JM. β-agonists and asthma: too much of a good thing? J Clin Invest. 112:495–7.
32.
Rodrigo G, Rodrigo O, Burschtin O. A meta-analysis of the effects of ipratropium bromide in adults with acute asthma. Am J Med. 107(4):363–70.
33.
Spitzer WO. The use of β agonists and the risk of death and near death from asthma. N Engl J Med. 326:501–6.
34.
Dennis SM, Sharp SJ, Vickers MR, Frost CD, Crompton GK, Barnes PJ, et al. Regular inhaled salbutamol and asthma control: the TRUST randomised trial. Therapy Working Group of the National Asthma Task Force and the MRC General Practice Research Framework Lancet. 355(9216):1675–9.
35.
Sears MR. Regular inhaled β-agonists treatment in bronchial asthma. Lancet. 336:1391–6.
36.
Barnes PJ, Chung KF. Questions about inhaled β-adrenoceptor agonists in asthma. Trends Pharmacol Sci. 13:20–3.
37.
Cazzola M, Matera MG. Safety of long-acting β-agonists in the treatment of asthma. Therapeutic Advances in Respiratory Disease. 1(1):35–46.
The statements, opinions and data contained in the journal are solely those of the individual authors and contributors and not of the publisher and the editor(s). We stay neutral with regard to jurisdictional claims in published maps and institutional affiliations.
